MATINAS BIOPHARMA HOLDINGS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $2.93 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.93M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.28M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.38M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.51M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $2.93M 10-K · filed 2026-03-31 | |
| 2024-12-31 | $5.28M 10-K · filed 2026-03-31 | |
| 2023-12-31 | $5.38M 10-K · filed 2025-04-15 | |
| 2022-12-31 | $4.51M 10-K · filed 2024-03-27 | |
| 2021-12-31 | $3.58M 10-K · filed 2023-03-15 | |
| 2020-12-31 | $3.22M 10-K/A · filed 2022-03-11 | |
| 2019-12-31 | $2.61M 10-K · filed 2021-03-29 | |
| 2018-12-31 | $1.29M 10-K · filed 2020-03-09 | |
| 2017-12-31 | $498.00K 10-K · filed 2019-04-01 | |
| 2016-12-31 | $549.00K 10-K · filed 2018-03-16 | |
| 2015-12-31 | $519.00K 10-K · filed 2017-03-31 | $518.54K 10-K · filed 2016-03-30 |
| 2014-12-31 | $489.02K 10-K · filed 2016-03-30 | |
| 2013-12-31 | $28.16K 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |